Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GLI1 | P08151 | 1/20 | 0.40 |
| ▸ | GLI2 | P10070 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL79972 | 1.00 | CYP3A4 (0.40) | CYP3A4GLI1GLI2MEN1CNR2 | |
| SCHEMBL3438794 | 1.00 | CYP3A4 (0.40) | CYP3A4GLI1GLI2MEN1CNR2 | |
| SCHEMBL17962954 | 1.00 | CYP3A4 (0.40) | CYP3A4GLI1GLI2MEN1CNR2 | |
| SCHEMBL11070476 | 0.78 | CYP3A4 (0.43) | CYP3A4GLI1GLI2 | |
| Alpha-Humulone SCHEMBL23460398 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL106386 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL31668762 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL29422612 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL23781774 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 | |
| Alpha-Humulone SCHEMBL17629686 | 0.75 | CYP3A4 (0.56) | CYP3A4GLI1GLI2MEN1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024124354-A1 | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PAIN OR OTHER DISORDERS | AIMA INC. (CA) | 2024-06-20 | — | — | WO | claimed |
| US-20230338329-A1 | CANNABINOID EMULSION COMPOSITION AND METHOD OF MANUFACTURING | GORE DOUGLAS (US) | 2023-10-26 | — | — | US | claimed |
| US-20220241199-A1 | CANNABINOID EMULSION COMPOSITION AND METHOD OF MANUFACTURE | GORE DOUGLAS (US) | 2022-08-04 | — | — | US | claimed |
| US-8129569-B2 | Photolabile fragrance storage substances | HENKEL AG & CO. KGAA (DE) | 2012-03-06 | — | — | US | claimed |
| US-20110027208-A1 | Photolabile Fragrance Storage Substances | HENKEL AG & CO. KGAA (DE) | 2011-02-03 | — | — | US | claimed |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | Doane Technology Group LLC (US) | 2026-05-26 | — | — | US | disclosed |
| US-20260124219-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF FOR IMMUNE MODULATION | SRIN THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-12485129-B2 | Water soluble compositions comprising purified cannabinoids | CANOPY GROWTH CORPORATION (CA) | 2025-12-02 | — | — | US | disclosed |
| US-12440501-B2 | Cannabinoid compositions and methods of use thereof for immune modulation | SRIN THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| EP-3503875-B1 | WATER SOLUBLE COMPOSITIONS COMPRISING PURIFIED CANNABINOIDS | CANOPY GROWTH CORP (CA) | 2025-09-17 | — | — | EP | disclosed |
| US-20250222053-A1 | COMPOSITIONS COMPRISING CANNABIS AND MUSHROOM EXTRACTS, AND USES THEREOF | COOKIES CREATIVE CONSULTING & PROMOTIONS, INC. | 2025-07-10 | — | — | US | disclosed |
| US-20250186466-A1 | ZLT-007 AND METHODS OF TREATING DIABETIC NEUROPATHY | ILERA THERAPEUTICS LLC | 2025-06-12 | — | — | US | disclosed |
| WO-2017091764-A1 | CANNABIS OIL COMPOSITIONS AND METHODS FOR PREPARATION THEREOF | CONSTANCE THERAPEUTICS, INC. (US) | 2017-06-01 | — | — | WO | disclosed |
| US-20160346339-A1 | METHODS FOR PREPARATION OF CANNABIS OIL EXTRACTS AND COMPOSITIONS | CONSTANCE THERAPEUTICS, INC. (US) | 2016-12-01 | — | — | US | disclosed |
| WO-2016123475-A1 | METHODS FOR PREPARATION OF CANNABIS OIL EXTRACTS AND COMPOSITIONS | CONSTANCE THERAPEUTICS, INC. (US) | 2016-08-04 | — | — | WO | disclosed |
| US-8129569-B2 | Photolabile fragrance storage substances | HENKEL AG & CO. KGAA (DE) | 2012-03-06 | — | — | US | disclosed |
| US-20110027208-A1 | Photolabile Fragrance Storage Substances | HENKEL AG & CO. KGAA (DE) | 2011-02-03 | — | — | US | disclosed |
| EP-1509181-A1 | PERSONAL CARE ARTICLE AND METHOD FOR INHIBITING ATTACHMENT OF YEAST TO SKIN | Kimberly-Clark Worldwide, Inc. (US) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004112819-A1 | COMPOSITIONS AND METHODS OF TREATMENT COMPRISING PLANT EXTRACTS | GELSTAT CORPORATION (US) | 2004-12-29 | — | — | WO | disclosed |
| WO-2003101356-A1 | PERSONAL CARE ARTICLE AND METHOD FOR INHIBITING ATTACHMENT OF YEAST TO SKIN | KIMBERLY-CLARK WORLDWIDE, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250222053-A1 | COMPOSITIONS COMPRISING CANNABIS AND MUSHROOM EXTRACTS, AND USES THEREOF | CNR1, CNR2, PLCB3 | CYP3A4 243/4885GLI1 11/4885GLI2 929/4885 |
| US-12485129-B2 | Water soluble compositions comprising purified cannabinoids | CNR2, CNR1, PTGES | CYP3A4 2530/4885GLI1 1320/4885GLI2 4478/4885 |
| US-20250186466-A1 | ZLT-007 AND METHODS OF TREATING DIABETIC NEUROPATHY | CNR2, CNR1, GPR119 | CYP3A4 3486/4885GLI1 123/4885GLI2 2306/4885 |
| US-20160346339-A1 | METHODS FOR PREPARATION OF CANNABIS OIL EXTRACTS AND COMPOSITIONS | CNR2, CNR1, EPHX2 | CYP3A4 1364/4885GLI1 2842/4885GLI2 4618/4885 |
| US-12636251-B1 | Glycoside-containing aqueous formulations having a lipophilic active component | CNR2, CNR1, LIPC | CYP3A4 1822/4885GLI1 4243/4885GLI2 3805/4885 |
| US-20260124219-A1 | CANNABINOID COMPOSITIONS AND METHODS OF USE THEREOF FOR IMMUNE MODULATION | DEGS1, CNR2, CNR1 | CYP3A4 1401/4885GLI1 3403/4885GLI2 3757/4885 |
| US-20110027208-A1 | Photolabile Fragrance Storage Substances | TRPA1, NISCH, TRPV1 | CYP3A4 177/4885GLI1 3545/4885GLI2 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.